A recently published study suggested that SYNE1 mutation was associated with a higher TMB and a worse survival in clear cell renal cell carcinoma and may enhance the response to PD‐1/PD‐L1 blockade therapy [40]. Here, SYNE1 is linked to clear cell renal carcinoma.